Table 1.

Patient demographics and baseline characteristics

	AZD4877 dose†
	10 mg (N = 3)	15 mg (N = 3)	20 mg (N = 6)	25 mg (N = 6)	Total (N = 18)
Age (years)
Mean (SD)	66.7 (4.0)	62.7 (5.5)	62.2 (10.7)	61.3 (9.6)	62.7 (8.4)
Range	63–71	59–69	45–73	50–75	45–75
Gender, N (%)
Male	2 (67)	2 (67)	1 (17)	2 (33)	7 (39)
Female	1 (33)	1 (33)	5 (83)	4 (67)	11 (61)
WHO performance status, N (%)
Normal activity (0)	1 (33)	3 (100)	2 (33)	2 (33)	8 (44)
Restricted activity (1)	2 (67)	0	4 (67)	4 (67)	10 (56)
Primary tumor site, N (%)
Lung	1 (33)	0	3 (50)	2 (33)	6 (33)
Breast	0	1 (33)	0	2 (33)	3 (17)
Pleura/pleural effusion	0	0	1 (17)	0	1 (6)
Prostate	0	1 (33)	0	0	1 (6)
Stomach	0	0	1 (17)	0	1 (6)
Colon	1 (33)	0	0	0	1 (6)
Other‡	1 (33)	1 (33)	1 (17)	2 (33)	5 (28)

^†Dose assigned on day 1 of cycle 1.

^‡Other tumor sites include: thymus (2), ureter (1), renal/prostate (1) and primary unknown tumor (1).

SD = standard deviation; WHO = World Health Organization.